RORhianna O'SUllivan

Rhianna O'SUllivan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rhianna O'SUllivan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epithelial Stem Cell Fate Determines Chemoradiotherapy Response in Rectal Cancer

    by Nick Li, Fiza Ishaqwala, Thomas A. Wright, Alistair Wilkinson, Petra Vlckova, Katherine Trevers, Rhianna O’SUllivan, Shauna Crampsie, Ewa Basiarz, Sierra Vanderkamp, et al.

    SUMMARY: Rectal cancers are often treated with neoadjuvant chemoradiotherapy (CRT), yet 85% of patients do not achieve a pathological complete response. To identify the molecular determinants of CRT response, we profiled the single-cell signalling, DNA-damage, cell-cycle, apoptotic, and cell-fate responses of 2,769 patient-derived organoid cultures treated with CRT, cancer-associated fibroblasts (CAFs), and signal-rewiring agents. We find that CRT response is determined by stem cell-fate. CRT triggers comparable DNA-damage in isogenic proliferative (proCSC) and revival (revCSC) colonic stem cells, but proCSC retain damage and die whereas revCSC resolve damage and persist. Both CRT and CAFs drive proCSC to a common treatment-resistant revCSC fate and high revCSC predicts worse survival in patients. Pharmacologically constraining stem-cell plasticity increases CRT sensitivity, and Spatial Perturbation of ARrayed Tumour Assembloids (SPARTA) confirms YAP/TEAD inhibition improves chemotherapy responses in human stromal-tumour models. These results suggest that cancer cell-fate, not genotoxic damage itself, ultimately governs response to standard-of-care chemoradiotherapy. HIGHLIGHTS: Rectal cancer stem cell-fate determines chemoradiotherapy-induced apoptosis proCSCs retain DNA-damage and die, whereas revCSCs repair damage and persist CAFs and chemoradiotherapy converge on a common chemo-radioresistant revCSC state SPARTA reveals TEAD inhibition blocks DNA-repair persisters in stromal assembloids

  • Open Access

    Stromal Prostaglandin is a Dominant Spatial Regulator of Cell-fate Plasticity in Colorectal Cancer

    by Corinne Molyneux, Rhianna O'SUllivan, Eoghan J. Mulholland-Illingworth, Joshua W. Moore, Nick Li, Petra Vlckova, Raheleh Amirkhah, Aurelie Dobric, Shauna Crampsie, Alistair Wilkinson, et al.

    Colorectal cancer (CRC) tumours with high stromal content have a worse outcome, but the mechanisms governing this are unclear. Using high-throughput single-cell perturbation analysis of CRC patient-derived organoids (PDOs) and cancer-associated fibroblasts (CAFs) we find that epithelial cells with high stromal-communication potential are marked by the transcriptional co-repressor DACH1 . To define the causal regulators of stromal-epithelial signalling, we developed a novel CRISPR screening platform to perturb the CAF secretome and measure epithelial stem cell responses at single-cell resolution. Intercellular CRISPR screening and full factorial ligand analysis revealed that stromal Prostaglandin E2 (PGE 2 ) is a dominant regulator of CRC cell-fate plasticity. Stromal PGE 2 converts DACH1 + epithelia from a chemosensitive proliferative colonic stem cell (proCSC) fate into a chemorefractory and pro-metastatic revival colonic stem cell (revCSC) fate. PGE 2 -driven epithelial transdetermination is rapid and reversible, providing an acute mechanism for stromal-driven plasticity in CRC tumours. Genetic and pharmacological inhibition of stromal COX2 inhibits epithelial plasticity, trapping CRC epithelia in an anti-metastatic and chemosensitive proCSC fate. PTGS2 + CAFs support a spatially resolved revCSC to proCSC plasticity gradient in human CRC tumours marked by increasing DACH1 expression. These results reveal that stromal prostaglandin is a dominant spatial regulator of poor-prognosis cell-fates and may explain the benefit of anti-COX therapies in both preventing and treating CRC.


  • Open Access

    Ephrin inhibition disrupts stromal-cancer crosstalk and reduces metastasis in pancreatic cancer

    by Cerian L. Bolton, Rhianna O'Sullivan, Guillem Fuertes-Marin, Francis Sprouse, Hanghang Wang, Shinelle Menezes, Amandine C. Tan, Sabrina Simoncelli, Angus J. M. Cameron, John F. Marshall, et al.

    Cancer associated fibroblasts (CAFs) are critical drivers of disease progression and metastasis within the pancreatic tumour microenvironment. Using a 3D spheroid model of CAF-led invasion, we identified complementary expression of ephrin family receptors (EPHB2) and ligands (EPHRINB2) between cancer cells and CAFs, implicating this bidirectional signalling family in tumour progression. Through pancreatic stellate cell-derived CAFs isolated from genetically modified mouse models, where EphrinB was either lacking or modified by a gain-of-function mutation, we identified both forward and reverse signalling to be required for invasion. In a syngeneic murine orthotopic model of pancreatic cancer, we show that first-in-class tetramerisation inhibitors of Eph/Ephrin interactions can reduce local invasion in primary tumours, and significantly decrease metastatic tumour spread across multiple organ sites. Our data highlight Ephrin signalling as a critical nexus for CAF-cancer crosstalk and establish a foundation for the clinical development of targeted EPH-EPHRIN inhibitors to counter metastatic invasion.

  • Open Access

    Figure 2 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Single-cell phenoscaping of γδ T-cell anti-PDO cytotoxicity. A, Experimental design and PDO27 B7-H3 expression measured by flow cytometry. B, γδ T-cell EMD PHATE at phenoscape (middle) and single-cell (insets) resolution. ×180 γδ T-cell–PDO cultures. EMD scores were calculated relative to unmodified-γδ monoculture controls to capture changes during stIL15 transduction and γδ coculture with PDO. C, γδ T PHATE annotated by PDO apoptosis. D, Therapeutic apoptosis via AIC or ADCC per γδ T-cell donor. Mean ± SD of triplicate samples. Two-way ANOVA with Sidak multiple comparisons test. The gray bar compares AIC; the orange bar compares cytotoxicity from AIC + B7-H3 mAb. E, ADCC killing in parental and B7-H3 CRISPR knockout PDO 27 demonstrate antigen specificity of ADCC killing. Unpaired t test (apoptosis values). Mean ± SD of quintuplet samples. F,x̄EMD of γδ T cells in monoculture or coculture with PDO27. Mean of six replicate samples per donor. The reference for x̄EMD scores for all conditions, including monoculture conditions, was calculated relative to monoculture controls. G, γδ T-cell S-phase ± PDOs. Six replicates per donor, with overall mean across all donors plotted. Two-way ANOVA with Tukey multiple comparisons test. H, EMD heatmap of stIL15-γδ T-cell PTM signaling and immunophenotyping markers ± B7-H3 mAb compared with monoculture controls for each stIL15-γδ T-cell donor. EMD scores were calculated relative to monoculture controls for each donor and treatment. ns, not significant; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure 4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Regulation of γδ T cells correlates with anti-PDO cytotoxicity. A, Single-cell PHATE of x10 PDOs + stIL15-γδ T cells ± B7-H3 mAb. B, PDO apoptosis via AIC or ADCC per γδ T donor across x10 PDOs. Two-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. C, Correlation of γδ x̄EMD with anti-PDO cytotoxicity during AIC, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. D, Correlation of γδ x̄EMD with anti-PDO cytotoxicity + B7-H3 mAb, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. E, stIL15-γδ PTM signaling with PDOs ± B7-H3 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

  • Open Access

    Figure 5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    B7-H3 mAb facilitates Fc receptor–dependant ADCC by stIL15-γδ T cells. A, Therapeutic apoptosis by stIL15-γδ T cells ± mAb ± mAb (Fc null), against colorectal cancer PDO 141. Two-way ANOVA with Dunnett multiple comparisons test. Mean ± SD of triplicate samples. B, Correlation between therapeutic apoptosis and B7-H3 epitope availability. The same clone of B7-H3 mAb was conjugated into the CyTOF staining panel to calculate the relative availability of B7-H3 epitope. C, EMD scores of stIL15-γδ T-cell granzyme B expression calculated relative to untreated coculture controls. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. D, Decrease in stIL15-γδ T-cell % DNAM-1 expression relative to monoculture controls for each treatment. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

  • Open Access

    Figure 7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Multimodal γδ T-cell cytotoxicity overcomes cellular therapy immunomodulation. γδ T-cell signaling networks following stIL15 transduction, coculture with PDO, and addition of B7-H3 mAb. Nodes are colored according to γδ EMD scores computed from >4 million cells across 576 conditions. Bottom, γδ cell-state histograms. Each cell-state phase is presented as the mean ± SD (n = 129–138). ITAM, immunoreceptor tyrosine-based activation motif.

  • Open Access

    Figure S5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Regulation of stIL15-γδs signalling and immunophenotype by CRC PDOs with or without anti-B7-H3 mAb

  • Open Access

    Figure S3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Phenotype of stIL15-γδ T cells when co-cultured with CRC PDO27

  • Open Access

    Figure S7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation

    by Callum Baird Nattress, Rhianna O’sUllivan, Daniel Fowler, Colin Hutton, Petra Vlckova, Jahangir Sufi, Magdalena Buschhaus, Ewa Basiarz, Maria Ramos Zapatero, Ferran Cardoso Rodriguez, et al.

    Relationship between stIL15-γδ cytotoxicity and γδ T cell and PDO phenotypes